News|Videos|November 16, 2023
Exploring Treatment Strategies for Lymphoma: CAR T-Cell, Tafasitamab, and Clinical Trials
Author(s)Matthew A. Lunning, DO, FACP
An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
2
Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia
3
FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer
4
c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC
5